

FINANCIAL TEAR SHEET

CORPORATE PROFILE

Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.

PRIMARY IR CONTACT

Investor Relations
Phone: 647-479-9825
E-mail: ir@aptose.com

STOCK PERFORMANCE

APTO (COMMON STOCK)

Exchange	TSX (Canadian Dollar)
Price	Can\$4.58
Change (%)	▼ 0.09 (1.93%)
Volume	20,014
52 Week Low	Can\$1.32
Market Cap	Can\$145,091,894
Rolling EPS	-0.73
PE Ratio	0
Shares Outstanding	31,068,928
Data as of May 25, 2018 11:30 a.m. ET	

APTO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	\$3.56
Change (%)	▼ 0.07 (1.93%)
Volume	257,928
52 Week Low	\$1.00
Market Cap	\$112,780,209
Rolling EPS	-0.57
PE Ratio	0
Shares Outstanding	31,068,928
Data as of May 25, 2018 12:16 p.m. ET	



RECENT PRESS RELEASES & UPCOMING EVENTS

May 17, 2018

Aptose to Present New CG'806 Data at the 23rd Congress of the European Hematology Association

May 10, 2018

Aptose Reports Results for the First Quarter Ended March 31, 2018

May 7, 2018

Aptose Exercises Early Option for CG-806 License From CrystalGenomics

Date	Title
June 5, 2018 10:00 a.m. PT	Aptose Biosciences Inc. Annual Shareholder Meeting Location 1540 Camino Del Mar Del Mar, CA 92014 US
June 15, 2018 5:30 p.m. CET	Aptose Biosciences Inc. at 23rd Congress of the European Hematology Association

SEC FILINGS

Filing Date	Form
May 17, 2018	6-K
May 10, 2018	6-K
May 10, 2018	6-K
May 9, 2018	6-K

CORPORATE GOVERNANCE

William G. Rice, Ph.D.	Chairman, President & Chief Executive Officer
Daniel D. Von Hoff, M.D., F.A.C.P.	Senior Vice President, Medical Affairs
Stephen B. Howell, M.D.	Acting Chief Medical Officer
Gregory Chow	Senior Vice President, Chief Financial Officer
Ernest Kitt	Vice President, Development and Technical Operations

Data provided by Nasdaq. Minimum 15 minutes delayed.